Medytoxin (botulinum toxin type A) / Sun Pharma, Medytox - LARVOL DELTA

A 12-Week Prospective, Double-Blind, Multicenter, Randomized Study Comparing 100 Units of Abobotulinum Toxin Type A (Dysport®) and 33.33 Units of Neubotulinum Toxin Type A (Neuronox®) for the Treatment of Hemifacial Spasm. (PubMed, Toxins (Basel)) - "Both Neu-BoNT-A and Abo-BoNT-A were safe and effective in treating HFS. However, Neu-BoNT-A was more effective in HFS with minimal symptoms without disability and Abo-BoNT-A more effective in HFS with greater duration of disability."

Clinical • Journal • CNS Disorders • Depression • Psychiatry

Sub-picosecond photodynamics of small neutral copper oxide clusters. (PubMed, Phys Chem Chem Phys) - "The ultrafast dynamics of neutral copper oxide clusters (CunOx, n < 5) are reported using femtosecond pump probe spectroscopy in the gas phase...Once the oxygen atoms exceed the number of copper atoms, a weakly bound superoxide O2 unit forms, exhibiting a higher spin state. All clusters that are not in the lowest spin configuration demonstrate fragmentation."

Journal

DNHFS: Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Rajavithi Hospital | Trial completion date: Apr 2024 ➔ Aug 2026 | Trial primary completion date: Mar 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date

High performance nonenzymatic electrochemical sensors via thermally grown Cu native oxides (CuNOx) towards sweat glucose monitoring. (PubMed, Analyst) - "The selectivity, when tested with common interferants found in human sweat and blood, showed an RSD of 4.32%. We hope that the electrocatalytic efficacy of the thermally grown CuNOx sensors for glucose sensing can introduce new avenues in the fabrication of sweat glucose sensors."

Journal • Diabetes • Metabolic Disorders

Evaluation of botulinum toxin type A for treating post burn hypertrophic scars and keloid in children: An intra-patient randomized controlled study. (PubMed, J Cosmet Dermatol) - "The botulinum toxins proved its efficacy and safety in treatment of hypertrophic scars and keloid in children. It improved the associated itching and pain. Moreover it improves the pliability, erythema, and thickness of the scars."

Journal • Dermatology • Fibrosis • Immunology • Pain

DNHFS: Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Rajavithi Hospital | Trial completion date: Apr 2022 ➔ Apr 2024 | Trial primary completion date: Mar 2022 ➔ Mar 2024

Trial completion date • Trial primary completion date

Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice. (PubMed, Toxicon X) - "The treatment using Botox, Botulift, and Xeomin were able to induce antinociceptive effects in both phases of the formalin-induced pain animal model, however, Dysport and Prosigne reduced the response in neither of them. Our data suggest that the treatment using different formulations of BoNT-A is not similar in efficacy as analgesics when evaluated in formalin-induced orofacial pain in mice."

Journal • Preclinical • CNS Disorders • Migraine • Pain

DNHFS: Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients (clinicaltrials.gov) - P3; N=120; Not yet recruiting; Sponsor: Rajavithi Hospital; Initiation date: Jan 2021 ➔ Jan 2022

Clinical • Trial initiation date

NTCD: Neubotulinum Toxin Injection in Cerivical Dystonia (clinicaltrials.gov) - P3; N=50; Completed; Sponsor: Rajavithi Hospital; Recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Dystonia • Movement Disorders

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines (clinicaltrials.gov) - P2; N=200; Completed; Sponsor: Medy-Tox; Active, not recruiting ➔ Completed; Trial primary completion date: Aug 2019 ➔ Sep 2020

Clinical • Trial completion • Trial primary completion date

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines (clinicaltrials.gov) - P2; N=150; Completed; Sponsor: Medy-Tox; Active, not recruiting ➔ Completed; Trial primary completion date: Aug 2019 ➔ Aug 2020

Clinical • Trial completion • Trial primary completion date

DNCD: Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia (clinicaltrials.gov) - P3; N=52; Completed; Sponsor: Rajavithi Hospital; Enrolling by invitation ➔ Completed

Clinical • Trial completion • CNS Disorders • Dystonia • Movement Disorders

NTCD: Neubotulinum Toxin Injection in Cerivical Dystonia (clinicaltrials.gov) - P3; N=50; Recruiting; Sponsor: Rajavithi Hospital; Initiation date: Oct 2020 ➔ Jan 2019

Clinical • Trial initiation date • CNS Disorders • Dystonia • Movement Disorders

DNHFS: Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients (clinicaltrials.gov) - P3; N=120; Not yet recruiting; Sponsor: Rajavithi Hospital

Clinical • New P3 trial

NTCD: Neubotulinum Toxin Injection in Cerivical Dystonia (clinicaltrials.gov) - P3; N=50; Recruiting; Sponsor: Rajavithi Hospital

Clinical • New P3 trial • CNS Disorders • Dystonia • Movement Disorders

Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis (clinicaltrials.gov) - P3; N=220; Completed; Sponsor: Medy-Tox; Recruiting ➔ Completed; Trial completion date: Aug 2020 ➔ Sep 2019

Clinical • Trial completion • Trial completion date

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy (clinicaltrials.gov) - P3; N=180; Completed; Sponsor: Medy-Tox; Recruiting ➔ Completed

Clinical • Trial completion

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder (clinicaltrials.gov) - P3; N=216; Active, not recruiting; Sponsor: Medy-Tox; Recruiting ➔ Active, not recruiting; Trial completion date: Aug 2020 ➔ Aug 2021

Clinical • Enrollment closed • Trial completion date • Overactive Bladder

DNCD: Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia (clinicaltrials.gov) - P3; N=50; Enrolling by invitation; Sponsor: Rajavithi Hospital; Recruiting ➔ Enrolling by invitation

Clinical • Enrollment status • Dystonia • Movement Disorders

Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers (clinicaltrials.gov) - P1; N=13; Recruiting; Sponsor: Medy-Tox

New P1 trial • Biosimilar

Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm. (PubMed, Korean J Ophthalmol) - "In this study, we showed that repetitive, long-term BoNT-A injections are considered a stable and effective treatment for essential blepharospasm in terms of consistent injection dose and maintenance of treatment efficacy. However, the duration of long-term efficacy could be decreased in patients injected repetitively."

Clinical • Journal • Biosimilar • Ophthalmology

Ministry OKs Medytox’s BTX in treating stiff upper limb muscles (Korea Biomedical Review) - "Coretox, the company’s pure botulinum toxin (BTX) product...Medytox is also conducting clinical trials to expand the indication of the drug in treating...chronic migraine (clinical phase 2)."

New P2 trial

Neurotoxin Impurities: A Review of Threats to Efficacy. (PubMed, Plast Reconstr Surg Glob Open) - "Well-established products [especially abobotulinumtoxinA (Dysport), onabotulinumtoxinA (Botox) and Xeomin] are accompanied by comprehensive and long-ranging clinical evidence on safety and efficacy in esthetic facial indications, which still remains undisclosed for many of the recently introduced toxins. Clinicians need this information as patients will require repeated BoNT treatments and may be unnecessarily but cumulatively exposed to potential immunogens. To underscore the need for caution and further evidence, we review some of the issues surrounding BoNT/A-induced immunogenicity and antibody-induced treatment failures and argue that using highly purified toxins that do not negatively impact patient outcomes is a prudent clinical decision."

Clinical • Journal

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines (clinicaltrials.gov) - P4; N=300; Completed; Sponsor: Medy-Tox; Recruiting ➔ Completed; Trial completion date: May 2020 ➔ May 2019

Clinical • Trial completion • Trial completion date

Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study. (PubMed, Korean J Ophthalmol) - "Neuronox and Botox are comparable in terms of their safety and efficacy in the management of BEB."

Clinical • Journal